EGFR and pachyonychia congenita: Conclusively, the findings of this study revealed EGFR as the most important target of quercetin in DRPC and further establish a scientific rationale for the exploration of quercetin in PC, especially as a combinational therapy with docetaxel in the treatment of DRPC.